BTK Inhibitors Show Similar Benefits in CLL Available to Purchase

In a phase III trial comparing acalabrutinib with ibrutinib in patients with previously treated chronic lymphocytic leukemia, researchers found that progression-free survival for the two BTK inhibitors was the same. However, acalabrutinib proved to be better tolerated, perhaps due to its greater selectivity.